{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:22:51Z","timestamp":1777335771622,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>During 2020 and immediately prior to the COVID-19 pandemic, Sudan was experiencing multiple emergencies including violence, seasonal flooding, and vector-borne disease outbreaks. After more than ten years since its last case of wild poliovirus, Sudan declared a circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak on 9 August 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>cVDPV2 outbreak response data and programme documents of the Federal Ministry of Health and WHO were reviewed. Surveillance data was verified through WHO-recommended procedures for detecting and characterizing polioviruses from stool and sewage samples collected from acute flaccid paralysis (AFP) cases and the environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This outbreak in Sudan led to a total of 58 confirmed cases of cVDPV2 from 15 of the 18 states. Two nationwide vaccination campaigns were held to increase immunity of children under-five against poliovirus type 2. Funding challenges were overcome by intense additional resource mobilization from in-country sources. The funding gap was bridged from domestic resources (49%) sourced through GPEI partners, and in-country humanitarian funding mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During an outbreak response and challenge of funding shortfall, mobilizing in-country resources is possible through coordinated approaches, regular communication with partners, disaggregation of needs, and matching in-kind and financial support to fill gaps. A cVDPV2 outbreak requires a fast, resourced, and quality response to stop virus circulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-15675-y","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:02:24Z","timestamp":1705665744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020\u20132021"],"prefix":"10.1186","volume":"24","author":[{"given":"Mohammed Taufiq","family":"Mashal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalya","family":"Eltayeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Higgins-Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael Suleiman","family":"El Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni\u2019ma Saeed","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"15675_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0140-6736(20)32629-5","volume":"397","author":"KM Thompson","year":"2020","unstructured":"Thompson KM. Poliovirus vaccine options: another step forward. The Lancet. 2020;397:2\u20133.","journal-title":"The Lancet"},{"issue":"49","key":"15675_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.15585\/mmwr.mm7049a1","volume":"70","author":"MM Alleman","year":"2021","unstructured":"Alleman MM, Jorba J, Henderson E, et al. Update on vaccine-derived Poliovirus Outbreaks \u2014 Worldwide, January 2020\u2013June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"15675_CR3","unstructured":"WHO. 14th meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia. Sept 20\u201321., 2015. Summary of findings, decisions and recommendations. https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/1Report.pdf. Accessed 4 Sept 2022."},{"key":"15675_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","volume":"65","author":"LM Hampton","year":"2016","unstructured":"Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine\u2014 worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934\u201338.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"15675_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.aba1238","volume":"368","author":"GR Macklin","year":"2020","unstructured":"Macklin GR, O\u2019Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401\u201305.","journal-title":"Science"},{"issue":"3","key":"15675_CR6","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1016\/S2666-5247(22)00042-8","volume":"3","author":"P Venkatesan","year":"2022","unstructured":"Venkatesan P. Global polio eradication set back by COVID-19 pandemic. The Lancet Microbe. 2022;3(3):E172.","journal-title":"The Lancet Microbe"},{"key":"15675_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","volume":"26","author":"RJ Duintjer Tebbens","year":"2006","unstructured":"Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26:1471\u2013505.","journal-title":"Risk Anal"},{"issue":"2","key":"15675_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","volume":"22","author":"LV Cooper","year":"2022","unstructured":"Cooper LV, Bandyopadhay AS, Gumede N, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. The Lancet Infect Dis. 2022;22(2):284\u201394.","journal-title":"The Lancet Infect Dis"},{"key":"15675_CR9","unstructured":"Global Polio Eradication initiative, circulating Vaccine Derived Poliovirus. https:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/circulating-vaccine-derived-poliovirus\/. Accessed 4 Sept 2022."},{"key":"15675_CR10","unstructured":"Sudan Polio GPEI. Outbreak 2009. https:\/\/reliefweb.int\/report\/sudan\/sudan-polio-outbreak-situation-7-apr-2009. Accessed 30 March 2023."},{"key":"15675_CR11","unstructured":"WHO. Progress in interrupting wild poliovirus circulation in countries with re-established transmission: Africa, 2009\u20132010. Weekly Epidemiological Record. 2011. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/241729\/WER8612_104-112.PDF. Accessed 30 March 2023."},{"issue":"14","key":"15675_CR12","first-page":"357","volume":"58","author":"CDC","year":"2009","unstructured":"CDC. Wild poliovirus type 1 and 3 importations --- 15 countries, Africa, 2008\u20132009. MMWR Wkly. 2009;58(14):357\u201362. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5814a1.htm. Accessed 30 March 2023.","journal-title":"MMWR Wkly"},{"issue":"18","key":"15675_CR13","first-page":"667","volume":"70","author":"J Tuma","year":"2021","unstructured":"Tuma J, Wilkinson AL, Diop OM, et al. Surveillance to track progress towards eradication worldwide, 2019\u20132020. MMWR. 2021;70(18):667\u201373.","journal-title":"MMWR"},{"key":"15675_CR14","unstructured":"GPEI Standard Operating Procedures for Responding to a Poliovirus Outbreak 4.0. 2022. https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/07\/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf. Accessed 4 Sept 2022."},{"issue":"2","key":"15675_CR15","first-page":"135","volume":"1","author":"EM Eltayeb","year":"2006","unstructured":"Eltayeb EM, Haithami SS, El Sayed EA. Combating an outbreak of poliomyelitis in Sudan following wild poliovirus importation: a success story. Sud J Public Health. 2006;1(2):135\u20138.","journal-title":"Sud J Public Health"},{"key":"15675_CR16","unstructured":"Sudan Health Cluster Annual Report., 2020 Health Response. https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/sudan_health_cluster_annual_report_-_2020_response_%20%281%29.pdf. Accessed 4 Sept 2022."},{"key":"15675_CR17","unstructured":"Federal Ministry of Health Sudan and WHO COVID-19 dashboard. https:\/\/worldhealthorg.shinyapps.io\/Outbreaks\/. Accessed 4 Sept 2022."},{"key":"15675_CR18","unstructured":"WHO. Circulating Poliovirus type 2-Sudan 01. September 2020. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/circulating-vaccine-derived-poliovirus-type-2-sudan. Accessed 4 Sept 2022."},{"key":"15675_CR19","unstructured":"World Health Organization, Emergency Response, Framework. 2017. 2nd ed. Geneva. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1087191\/retrieve. Accessed 29 March 2023."},{"issue":"suppl 1","key":"15675_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/10810731003695383","volume":"15","author":"GA Pirio","year":"2010","unstructured":"Pirio GA, Kaufmann J. Polio eradication is just over the horizon: the challenges of global resource mobilization. J Health Commun. 2010;15(suppl 1):66\u201383.","journal-title":"J Health Commun"},{"key":"15675_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12688\/gatesopenres.13524.1","volume":"6","author":"KM Thompson","year":"2022","unstructured":"Thompson KM, Kalkowska DA, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the global Polio Eradication Initiative. Gates Open Res. 2022;6:5.","journal-title":"Gates Open Res"},{"key":"15675_CR22","unstructured":"GPEI. Delivering on a promise, Polio Eradication Strategy 2022\u20132026. https:\/\/polioeradication.org\/gpei-strategy2022-2026\/. Accessed 4 Sept 2022."},{"key":"15675_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41577-021-00640-w","volume":"21","author":"A Mohammed","year":"2021","unstructured":"Mohammed A, Tomori O, Nkengosong JN. Lessons from the elimination of poliomyelitis in Africa. Nat Reviews Imm. 2021;21:823\u20138.","journal-title":"Nat Reviews Imm"},{"key":"15675_CR24","unstructured":"Immunization agenda. 2030. A global strategy to leave no one behind. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/strategies\/ia2030. Accessed 4 Sept 2022."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15675-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15675-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15675-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:03:27Z","timestamp":1705665807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15675-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["15675"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15675-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2075168\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare there is no conflict of interest for this paper. We do not have a commercial or other association that would pose a conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}